| Browse All

Sana Biotechnology, Inc. (SANA)

Healthcare | Biotechnology | Seattle, United States | NasdaqGS
3.52 USD +0.05 (1.441%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 3.50 -0.02 (-0.020%) ⇩ (April 17, 2026, 7:57 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆
Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.331184
AutoTheta0.331215
AutoETS0.331575
MSTL0.334829

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 48%
H-stat 5.15
Ljung-Box p 0.000
Jarque-Bera p 0.294
Excess Kurtosis -1.01
Attribute Value
Sector Healthcare
Debt to Equity Ratio 53.618
Market Cap 939,371,456
Forward P/E -6.63
Beta 2.07
Website https://www.sana.com

As of April 18, 2026, 10:29 p.m. EDT: Implied volatility is extremely compressed (ATM IV ~1.0-1.2 for longer dated), indicating a lack of recent moves or positioning. Short-term open interest is heavily skewed toward OTM calls (OTM OI % > 90% for April/May expirations), though strike 5.0 represents a significant pocket of support/resistance. The Put/Call ratio is below 1.0 across most maturations, speculating net bullish sentiment. However, the massive short interest (46.21%) and negative earnings (EPS -0.53) suggest the options market is pricing in high binary potential (black swan risk/reward) rather than steady accretion. The flat IV term structure suggests deglitching or low perceived near-term volatility.


Info Dump

Attribute Value
52 Week Change 1.2138364
Address1 188 East Blaine Street
Address2 Suite 400
All Time High 44.6
All Time Low 1.26
Ask 3.63
Ask Size 20
Audit Risk 6
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 3,964,100
Average Daily Volume3 Month 2,816,274
Average Volume 2,816,274
Average Volume10Days 3,964,100
Beta 2.065
Bid 3.45
Bid Size 20
Board Risk 7
Book Value 0.603
City Seattle
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 8
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.52
Current Ratio 1.889
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.63
Day Low 3.505
Debt To Equity 53.618
Display Name Sana Biotechnology
Earnings Timestamp 1,772,571,600
Earnings Timestamp End 1,778,184,000
Earnings Timestamp Start 1,778,184,000
Ebitda -178,208,000
Ebitda Margins 0.0
Enterprise To Ebitda -4.979
Enterprise Value 887,251,456
Eps Current Year -0.5804
Eps Forward -0.5311
Eps Trailing Twelve Months -0.96
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 3.4796
Fifty Day Average Change 0.04040003
Fifty Day Average Change Percent 0.011610538
Fifty Two Week Change Percent 121.383644
Fifty Two Week High 6.55
Fifty Two Week High Change -3.0300002
Fifty Two Week High Change Percent -0.46259543
Fifty Two Week Low 1.59
Fifty Two Week Low Change 1.93
Fifty Two Week Low Change Percent 1.2138364
Fifty Two Week Range 1.59 - 6.55
Financial Currency USD
First Trade Date Milliseconds 1,612,449,000,000
Float Shares 177,274,342
Forward Eps -0.5311
Forward P E -6.627754
Free Cashflow -53,566,752
Full Exchange Name NasdaqGS
Full Time Employees 142
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.06834
Held Percent Institutions 0.75235003
Implied Shares Outstanding 266,866,897
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-02-04
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Long Name Sana Biotechnology, Inc.
Market us_market
Market Cap 939,371,456
Market State CLOSED
Max Age 86,400
Message Board Id finmb_597313585
Most Recent Quarter 1,767,139,200
Net Income To Common -244,166,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 936,702,808
Number Of Analyst Opinions 7
Open 3.6
Operating Cashflow -143,828,000
Operating Margins 0.0
Overall Risk 8
Payout Ratio 0.0
Phone 206 701 7914
Post Market Change -0.01999998
Post Market Change Percent -0.5681813
Post Market Price 3.5
Post Market Time 1,776,470,264
Previous Close 3.47
Price Eps Current Year -6.064783
Price Hint 4
Price To Book 5.8374796
Profit Margins 0.0
Quick Ratio 1.758
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.44444
Region US
Regular Market Change 0.05
Regular Market Change Percent 1.44092
Regular Market Day High 3.63
Regular Market Day Low 3.505
Regular Market Day Range 3.505 - 3.63
Regular Market Open 3.6
Regular Market Previous Close 3.47
Regular Market Price 3.52
Regular Market Time 1,776,456,000
Regular Market Volume 3,231,336
Return On Assets -0.26004
Return On Equity -1.18704
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 266,866,897
Shares Percent Shares Out 0.1476
Shares Short 39,379,007
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 35,826,361
Short Name Sana Biotechnology, Inc.
Short Percent Of Float 0.401
Short Ratio 13.11
Source Interval 15
State WA
Symbol SANA
Target High Price 12.0
Target Low Price 7.0
Target Mean Price 8.57143
Target Median Price 7.0
Total Cash 138,382,000
Total Cash Per Share 0.519
Total Debt 86,262,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.96
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 3.9728
Two Hundred Day Average Change -0.45280004
Two Hundred Day Average Change Percent -0.11397504
Type Disp Equity
Volume 3,231,336
Website https://www.sana.com
Zip 98,102